| • | Cost-effectiveness
of lopinavir/r tablets compared
to atazanavir + ritonavir
in antiretroviral experienced patients in the UK,
Spain, Italy, and France based on results from BMS AI424-045.
KN
Simpson and others.
PDF Poster Abstract |
| • | Efficacy
and safety of lopinavir/r and atazanavir
without a nucleoside backbone in antiretroviral therapy experienced HIV-infected
subjects. DA Parks and others.
PDF Poster Abstract |
| • | Tolerability and preference of lopinavir/ritonavir
(Kaletra) capsules versus tablets as single agent therapy
(IMANI-2). J Gathe and others.
PDF Poster Abstract |
| • | Lack of sex differences in once-daily lopinavir/ritonavir
(LPV/r) pharmacokinetic (PK) Profile. I Ofotokun and others.
PDF Poster Abstract |
| • | Significant
improvements in self-reported gastrointestinal (GI) tolerability, quality of life
(QoL), patient satisfaction, and adherence with lopinavir/ritonavir (LPV/r) after switching from BID soft-gel
capsule (SGC) to BID tablets (TAB).
S
Schrader and others.
PDF Poster Abstract |
| • | Improvements
in self-reported adherence & gastrointestinal adverse effects (AEs) with lopinavir/ritonavir (LPV/r)
after switching from soft-gel capsule (SGC) to tablet (TAB) varies by ethnicity.
S Schrader
and others.
PDF Poster Abstract |
| • | Relationship between Time to Viral Load Suppression and First Month Adherence
to Prescribed Antiretroviral Therapy. RA Rode and others.
PDF Poster Abstract |
| • | Lipid-profile of lopinavir/ritonavir (LPV/r) in
an 18-month French observational prospective cohort (Kaleobs
cohort). M
Dupon and others.
PDF Poster Abstract |
| • | Efficacy
of lopinavir/ritonavir (LPV/r) in clinical practice:
an 18-month observational prospective cohort of 1315 patients (Kaleobs cohort).
J-M
Livrozet and others.
PDF Poster Abstract |
| • | Impact
of a lopinavir/ritonavir (LPV/r) monotherapy on self-reported side effects and global health
perception among antiretroviral-naive patients: 48-week analysis of the MONARK
Trial. B Spire and others.
PDF Poster Abstract |
| • | Predicted pharmacokinetics of lopinavir after
multiple dose administration of lopinavir/ritonavir
tablet to pediatric patients.W Liu and others.
PDF Poster
Abstract |
| • | Pharmacokinetics
of lopinavir and ritonavir
after multiple dose administration of lopinavir/ritonavir
tablet co-administered with efavirenz. C
E Klein and others.
PDF Poster
Abstract |
| • | Gastrointestinal
Complaints and use of Acid Reducing Agents are frequent in patients treated with
Antiretrovirals. N Ackad and others.
PDF Poster AbstractFOLLOWING ARE ABSTRACTS ONLY |
| • | Similar
virologic and immunologic response to efavirenz or lopinavir/ritonavir-based
HAART in a large cohort
ofantiretroviral-naïve patients with advanced HIV infection
F Pulido and others. |
| • | Long-term
follow-up of IMANI I: pilot study of the safety and efficacy of lopinavir/ritonavir (LPV/r) as single agent therapy (SAT) in HIV-1 antiretroviral (ARV)-naive
patients.
J Gathe,
Jr. and others. |
| • | Tolerability
of lopinavir/ritonavir (LPV/r) liquid in HIV+ adults
switched from the soft gelatin capsule (SGC).
J
Toy and others. |
| • | Placental
transfer of lopinavir, saquinavir, and ritonavir
K Weizsaecker
and others. |
| • | Lipids
and lipoproteins in HIV-subjects treated with lopinavir/ritonavir
(L) or atazanavir/ritonavir (A)
based antiretroviral therapy.
A Trein and
others. |
| • | P-glycoprotein
is inhibited by lopinavir and low-dose ritonavir
in HIV-infected patients and in healthy men.
C Wyen
and others |
| • | Crossover,
steady-state comparison of lopinavir/ritonavir (LPV/r) pharmacokinetics (PK) in women
of colour.
I R McNicholl and others. |
| • | A
study on the performance of combination of Kaletra and saquinavir twice-daily
regimen on a group of antiretroviral therapy experienced patients.
K Manavi and others.
|
| • | Different
rates of early viral load reduction with nevirapine or lopinavir/ritonavir-based
combination antiretroviral therapies in pregnant women.
C Bell and others. |
| • | Safety
assessment of lopinavir/ritonavir (LPV/r) in HIV+ and
hepatitis C (HCV) co-infected patients.
P
Cote and others. |
| • | Low
incidence of severe liver events (SLE) in HIV patients with and without hepatitis
C or B coinfection receiving lopinavir/ritonavir (LPV/r).
I Aguilar and others. |
| • | The
assessment of multi-locus gene effects upon lopinavir
pharmacokinetics
A Owen and others. |
| • | Plasma
lopinavir levels in a group of pregnant women on lopinavir,
ritonavir, zidovudine, and
lamivudine.
K Manavi and others |
| • | Exploring
the feasibility of dried blood spots for quantification of lopinavir,
nevirapine and efavirenz concentrations.
L Else and others.
|
|
| • | Failure
of lopinavir/ritonavir-containing regimen with newly
selected PI resistance mutations in an antiretroviral naive patient.
S Koch and others. |
| • | Triglycerides and small, dense low-density lipoprotein in HIV infected
patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy.
L Magenta and others
<—
Conference
Main Page |
